EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy.

摘要: The selection of colorectal cancer patients for anti-epidermal growth factor receptor (EGFR) antibody therapy is based on the determination their RAS mutation status-a strongly negative predictive factor-since protein target, EGFR, not a reliable predictor therapeutic response. In this study, we revisited EGFR issue using cohort 90 with KRAS exon2 wild-type who have been treated cetuximab therapy. Twenty-nine these had metastatic tissue available analysis. level expression in was determined by immunohistochemistry and evaluated H-score (HS) methodology. Progression-free survival (PFS) overall (OS) were according to EGFR-HS ranges both primary tissues Kaplan-Meyer statistics. case tumors, scores lower than HS = 200 associated significantly longer OS. tissues, all levels range chosen These results are explained fact that rarely maintained tumors. On other hand, high either tumors or multiple disease. This suggests prognostic role expression. However, multivariate analysis, one-sidedness remained strong independent survival. Previous studies demonstrated depends sidedness. Therefore, subgroup analysis left- right-sided cases performed tissues. metastic an confirmed better OS low protein-expressing cases. Collectively, data suggest another efficacy cancer.